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4-Aryl-4H-naphthopyrans derivatives: one-pot
synthesis, evaluation of Src kinase inhibitory and
anti-proliferative activities
Ali Rafinejad1, Asal Fallah-Tafti1, Rakesh Tiwari2, Amir Nasrolahi Shirazi2, Deendayal Mandal2, Abbas Shafiee1,
Keykavous Parang2, Alireza Foroumadi1 and Tahmineh Akbarzadeh1*
Abstract
Background: A series of 2-amino-4-aryl-4H-benzo[h or f]chromene-3-carbonitrile derivatives were synthesized and
evaluated for inhibition of Src kinase and cell proliferation in breast carcinoma (BT-20) cell lines.
Methods: The one-pot, three-component reaction of α or β-naphthol, malonitrile and an aromatic aldehyde in the
presence of diammonium hydrogen phosphate was afforded the corresponding 2-amino-4-aryl-4H-benzo[h or f]
chromene-3-carbonitrile derivatives, All target compounds were evaluated for inhibition of Src kinase and cell
proliferation in breast carcinoma (BT-20) cell lines.
Results: Among all tested compounds, unsubstituted 4-phenyl analog 4a showed Src kinas inhibitory effect with
IC50 value of 28.1 μM and was the most potent compound in this series. In general, the compounds were
moderately active against BT-20. 3-Nitro-phenyl 4e and 3-pyridinyl 4h derivatives inhibited the cell proliferation of
BT-20 cells by 33% and 31.5%, respectively, and found to be more potent compared to doxorubicin (25% inhibition
of cell growth).
Conclusion: The data indicate that 4-aryl-4H-naphthopyrans scaffold has the potential to be optimized further for
designing more potent Src kinase inhibitors and/or anticancer lead compounds.
Keywords: Anticancer activity, Carbonitrile, Naphthopyrans, Protein kinase, Src kinase
Introduction
c-Src kinase is one of the most widely studied member
of the Src (acronym of sarcoma) family of non-receptor
protein tyrosine kinases (PTKs). c-Src acts as a critical
component in a number of signaling pathways that con-
trol cell growth, proliferation, invasion, and apoptosis
[1-3]. Previous studies have shown that c-Src kinase is
highly regulated and is active only at low levels in most
normal cells while it is upregulated in many human
cancers [4,5]. Most recently emerging data reveals that
the predominant consequences of increased c-Src activ-
ity in tumor cells results in reduction of cell adhesion,
facilitation of motility, and thereby promotion of an
invasive phenotype [6]. Interest in designing c-Src kinase
inhibitors as a treatment for cancer and in particular, as
an antiinvasion strategy has been increased in the last
decade. The current popularity of Src kinases as drug
targets is due to several factors including the positive
correlation between the development of cancer and the
upregulation of Src activity and reduction of cancer pro-
gression by inhibition of Src kinase in several types of
cancer [7-10].
Several c-Src kinase inhibitors have been identified over
the years [11]. Src kinase inhibitor scaffolds span a variety
of structural classes, including staurosporine as a standard
nonselective protein kinase inhibitor, pyrazolopyrimidine
(e.g., PP1, PP2) [12,13], anilinoquinazoline [14,15], and
quinolinecarbonitrile [16-18] derivatives. The Saracatinib
(AZD0530) [15,19] and Bosutinib (SKI-606) [20,21] with
anilinoquinazoline and 3-quinolinecarbonitrile cores, re-
spectively (Figure 1), are among potent Src kinase
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inhibitors, which are currently in clinical development for
the treatment of a wide range of tumor types. Since ATP
binding region is strongly conserved among protein
kinases, designing selective Src kinase inhibitors is still a
great challenge. Therefore, research is needed to explore
new scaffolds which selectively inhibit Src kinase domain.
Recently emerging data support the hypothesis that the
presence of a nitrile group in different scaffolds, such as
quinolinecarbonitrile (e.g., Bosutinib), and benzylidene-
malononitriles (tyrophostins (acronym of tyrosine phos-
phorylation inhibitors)), is crucial for protein kinase
inhibitory activity [22]. Compound A (Figure 2) [23] with
Figure 1 Chemical structures of some of the Src kinase inhibitors.
Figure 2 Benzylidene-malononitrile(tyrophstin) derivative as protein kinase inhibitor (A), Chemical structures of A771726, active
metabolite of Leflunomide, antiproliferative 4-aryl-4H-5,6-dihydronaphtho[1,2-b]pyran (compound B), and synthesized 4-Aryl-4H-
Naphthopyrans (4a-n).
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2-quinoline tyrophostin structure exhibit IC50 in the low
molecular range (IC50= 1.7 μM) against EFGR. Fur-
thermore, A771726 (Figure 2) with cyano hydroxyl
β-butenamide, which is the predominant active metabolite
of Leflunamide, has been identified as a tyrosine kinase in-
hibitor and antiproliferative agent [24,25]. This compound
was used as a starting lead for designing new antiproliferative
compounds that finally led to the identification of 4-aryl-4H-
5,6-dihydronaphtho[1,2-b]pyran B (Figure 2) as a new lead
compound with moderate activity on the mesenchymal stem
cell proliferation assay (IC50 = 13 μM) [25]. Different
derivatives of naphthopyranes have been synthesized since
then and showed multiple pharmacological effects, such as
anti-rheumatoid, anti-diabetic, anti-proliferative, and protease
inhibition effects [25,26].
We previously reported synthesis and evaluation of
4-aryl-4H-chromene-3-carbonitrile derivatives as Src
kinase inhibitors [27]. As part of our efforts to identify
new scaffolds as Src kinase inhibitors [28-35], herein we
report the synthesis and evaluation of selected 2 or
3-amino-4-aryl-4H-benzo[h or f]chromene-3-carbonitrile
derivatives 4a-n (Figure 2) that contains both nitrile and
naphthopyrane cores as Src kinase inhibitors or anti-
proliferative agents.
Methods
Materials
All starting materials, reagents, and solvents were
purchased from Merck AG (Germany). The purity of the
synthesized compounds was confirmed by thin layer
chromatography (TLC) using various solvents of differ-
ent polarities. Merck silica gel 60 F254 plates were ap-
plied for analytical TLC. Column chromatography was
performed on Merck silica gel (70–230 mesh) for purifi-
cation of the intermediate and final compounds. Melting
points were determined on a Kofler hot stage apparatus
(Vienna, Austria) and are uncorrected. 1H NMR spectra
were recorded using a Bruker 500 MHz spectrometer
(Bruker, Rheinstatten, Germany), and chemical shifts
were expressed as δ (ppm) with tetramethylsilane (TMS)
as an internal standard. The IR spectra were obtained on
a Shimadzu 470 (Shimadzu, Tokyo, Japan) spectropho-
tometer (potassium bromide disks). The mass spectra
were run on a Finnigan TSQ-70 spectrometer (Thermo
Finnigan, West Chester, OH, USA) at 70 eV. Elemental
analyses were carried out on a CHN-O-rapid elemental
analyzer (Heraeus GmbH, Hanau, Germany) for C, H,
and N, and the results were within ± 0.4% of the theoret-
ical values.
General procedure for the peparation of 2-amino-4-aryl-
4H-naphthopyran-3-carbonitrile derivatives 4a-n
In general, diammonium hydrogen phosphate (DAHR,
0.5 mmol) was added to a mixture of α or β-naphtol
(5 mmol), substituted aryl-aldehyde (5 mmol), and
malonitrile (5 mmol) in ethanol (10 mL) and water
(10 mL). The reaction mixture was stirred at room
temperature for 4 h. After cooling, the precipitated solid
was filtered, washed with cold ethanol, and crystallized
from the same solvent. The synthesized compounds were
characterized by IR, 1H NMR, mass spectrpscopy and
elemental analysis. Physicochemical and spectral proper-
ties of compounds 4a-n were consistent with the previ-
ously reported data [36,37].
c-Src kinase activity assay
The effect of synthesized compounds on the activity of c-Src
kinase was determined by HTScan Src Kinase Assay Kit,
catalogue number 7776 from Cell Signaling Technology
(Danvers, MA, USA); according to manufacturer’s proto-
col. Streptavidin-coated plates were purchased from Pierce
(Rockford, IL, USA). In brief, the kinase reaction was
started with the incubation of the 12.5 μL of the reaction
cocktail (0.5 ng/μL of GST-Src kinase in 1.25 mM DTT)
with 12.5 μL of prediluted compounds (dissolved in 1%
DMSO) for 5 min at room temperature. ATP/substrate
(25 μL, 20 μM/1.5 uM) cocktail was added to the mixture.
The biotinylated substrate (catalogue number 1366)
contains the residues surrounding tyrosine 160 (Tyr160)
of signal transduction protein and has a sequence of
EGIYDVP. The reaction mixture was incubated for 30
min at room temperature. The kinase reaction was
stopped with the addition of 50 μL of 50 mM EDTA (pH
8.0). The reaction solution (25 μL) was transferred into
96-well streptavidin plates (Pierce, part number 15125),
diluted with 75 μL double distilled water, and incubated at
room temperature for 60 min. At the end of the incuba-
tion, the wells were washed three times with 200 μL of
0.05% Tween-20 in PBS buffer (PBS/T). After that to each
well was added 100 μL of phosphotyrosine antibody
(P-Tyr-100) (1:1000 dilution in PBS/T with 1% BSA) and
the wells were incubated for another 60 min. After
washing three times with 0.05% Tween-20 in PBS/T, the
wells were incubated with 100 μL secondary anti-mouse
IgG antibody, which was HRP-conjugated (1:500 dilution
in PBS/T with 1% BSA) for next 30 min at room
temperature. The wells were washed five times with 0.05%
Tween-20 in PBS and then were incubated with 100 μL of
3,3',5,5'-tetramethylbenzidine dihydrochloride (TMB) sub-
strate for 5 min. The reaction was stopped by adding 100
μL/well of stop solution to each well and mixed well and
read the absorbance at 450 nm using a microplate reader
(Molecular devices, spectra Max M2). IC50 values of the
compounds were calculated using ORIGIN 6.0 (origin lab)
software. IC50 is the concentration of the compound that
inhibited enzyme activity by 50%. All the experiments
were carried out in triplicate [27].
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Cell culture and cell proliferation assay
Cell culture
Breast carcinoma BT-20 (ATCC no. HTB-19) cell lines
were obtained from American Type Culture Collection.
Cells were grown on 75 cm2 cell culture with EMEM
medium for breast carcinoma and supplemented with
10% fetal bovine serum (FBS), and 1% penicillin-
streptomycin solution (10,000 units of penicillin and 10
mg of streptomycin in 0.9% NaCl) in a humidified
atmosphere of 5% CO2, 95% air at 37°C.
Cell proliferation assay
Cell proliferation assay of compounds was evaluated in
BT-20 cells, and was compared with that of doxorubicin
(DOX)[38]. Cell proliferation assay was carried out using
CellTiter 96 aqueous one solution cell proliferation assay
kit (Promega, USA). Briefly, upon reaching about 75-
80% confluence, 5000 cells/well were plated in 96-well
microplate in 100 μL media. After seeding for 72 h, the
cells were treated with 50 μM compound in triplicate.
DOX (10 μM) was used as the positive control. Incubation
was carried out at 37°C in an incubator supplied with 5%
CO2 for 72 h. At the end of the sample exposure period
(72 h), 20 μL CellTiter 96 aqueous solution was added.
The plate was returned to the incubator for 1 h in a
humidified atmosphere at 37°C. The absorbance of the
formazan product was measured at 490 nm using
microplate reader. The blank control was recorded by
measuring the absorbance at 490 nm with wells
containing medium mixed with CellTiter 96 aqueous solu-
tion but no cells. Results were expressed as the percentage
of the control (DMSO without compound set at 100%).
The percentage of cell survival was calculated as (OD
value of cells treated with test compound - OD value of
culture medium) / (OD value of control cells – OD value
of culture medium) × 100%.
Results and discussion
Chemistry
Naphthopyran analogs described here (4a-n) were
synthesized following the synthetic routes outlined in
Figure 3. The compounds were synthesized according to
the previously reported general procedure by a one-pot
reaction [37] through the condensation of a substituted
aromatic aldehyde (1), malonitrile, and α or β-naphtol
(3, 5) in ethanol and water in the presence of diam-
monium hydrogen phosphate (Figure 4).
Src kinase inhibitory activity
The results of Src kinase inhibitory activity of
compounds 4a-n are shown in Table 1. Compounds 4a,
4d, 4i, 4m, and 4n exhibited higher Src kinase inhibitory
activity (IC50 =28.1– 34.7 μM in following order
4a>4i,4m>4n>4d) when compared with that of other
compounds. Unsubstituted phenyl analog 4a showed an
IC50 value of 28.1 μM and was the most potent compound
in this series. 2-Chlorophenyl substituted analog 4d was
one of the potent compounds in α-naphthol series with an
IC50 value of 34.7 μM. Similarly compound 4j with 3-
chlorophenyl substitution was a moderately effective com-
pound in β-naphthol series with an IC50 value of 41.7 μM.
In addition, 2,3-dichlorophenyl substituted compounds 4f
and 4l were among potent inhibitors in both α and
β-naphthol series of compounds. However, substitution of
2,6-dichlorophenyl in compound 4g led to loss of inhibitory
activity, suggesting that chloro substitution at positions 2
and 6 of phenyl ring is detrimental in Src kinase inhibition.
Compounds 4m and 4n with 3-hydroxyphenyl and 4-
methoxyphenyl moieties, respectively, were among potent
compounds in β-naphthol series. 3-Nitrophenyl substitu-
tion resulted in loss of activity in compounds 4e and 4k in
both α and β-naphthol series of compounds. Similarly
compounds 4b (4-F-Ph) and 4c (3-Br-Ph) did not show any
Figure 3 Inhibition of BT-20 cell proliferation by compounds 4a-n (50 μM) after 72 h incubation. The results are shown as the percentage
of the control DMSO that has no compound (set at 100%). All the experiments were performed in triplicate.
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significant inhibitory activity (IC50 > 150) against Src kinase.
On the other hand, compounds 4h with pyridine ring sub-
stitution and compound 4i with 1-methylnitroimidazole
moiety showed good inhibitory activity against Src kinase
compared to other phenyl substituted compounds.
Anti-proliferative activities
The effect of the inhibitors at the concentration of 50 μM on
the cell proliferation of breast carcinoma (BT-20) cell line
was evaluated (Figure 3). Compounds 4e and 4h inhibited
the cell proliferation of breast carcinoma cells (BT-20) by
33% and 31.5% (4h>4e), respectively (Figure 3). Compounds
4e and 4h found to be more potent on BT-20 cell
proliferation assay compared to doxorubicin, while com-
pound 4c with 24.8% cell proliferation inhibitory effect
against BT-20 cell line was as effective as doxorubicin (25%
inhibition of cell growth).
Although compound 4h was found to be a moderate
Src kinase inhibitor and a potent anti-proliferative agent
against BT-20 cell line, there were no significant correl-
ation between Src kinase inhibitory potency of the other
compounds with their growth inhibition activity against
cancer cells. Compounds 4a, 4d, 4i, 4m, and 4n with good
Src kinase inhibitory activity showed less potency in anti-
proliferation assay (0-21%). In contrast, compound 4e that
showed good anti-proliferative effect against breast carcin-
oma cells was a weak Src kinase inhibitor (IC50 > 150 μM).
It seems that in vitro enzymatic and cell-based assays
may not correlate well due to the diversity in solubility
and cellular uptake of the compounds. Further studies
are required to determine whether these compounds
have limited cellular uptakes that lead to their minimal
anti-proliferative activities.
Conclusions
A number of 2-amino-4-aryl-4H-benzo[h or f]chromene-3-
carbonitrile derivatives were prepared and evaluated for Src
Table 1 Inhibition of Src Kinase activity by 2-amino-4-
aryl-4H-naphtopyran-3-carbonitrile derivatives
O
NH2
4a-i
Ar
CN
O
CN
NH2
4j-n
Ar
Compounds Ar IC50 (μM)
a
4a Ph 28.1
4b 4-F-Ph > 150
4c 3-Br-Ph > 150
4d 2-Cl-Ph 34.7
4e 3-NO2-Ph > 150
4f 2,3-di(Cl)-Ph 41.7
4g 2,6-di(Cl)-Ph > 150
4h 36.5
4i 33.8
4j 3-Cl-Ph 41.7
4k 3-NO2-Ph > 150
4l 2,3-di(Cl)-Ph 38.9
4m 3-OH-Ph 33.8
4n 4-MeO-Ph 34.5
Staurosporin - 0.3
PP2 - 2.8
aThe concentration that inhibited enzyme activity by 50%.
Figure 4 One-pot synthesis of 4-Aryl-4H-Naphthopyrans 4a-n.
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kinase inhibitory and anticancer activities. In summary,
structure-activity relationship studies revealed that the
incorporation of less bulkier groups such as unsubstituted
phenyl at position of aryl is preferred and well tolerated
compared to other groups in generating Src inhibitory activ-
ity. The data provide insights for key structural requirements
for further optimization of chromene-carbonitrile derivatives
as a scaffold and generating more potent and selective Src
kinase inhibitors and/or anticancer agents.
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